{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:17:40Z","timestamp":1793128660110,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011516","name":"Beyond Batten Disease Foundation","doi-asserted-by":"publisher","award":["Beyond Batten Disease Foundation"],"award-info":[{"award-number":["Beyond Batten Disease Foundation"]}],"id":[{"id":"10.13039\/100011516","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005468","name":"Batten Disease Support and Research Association","doi-asserted-by":"publisher","award":["Batten Disease Support and Research Association"],"award-info":[{"award-number":["Batten Disease Support and Research Association"]}],"id":[{"id":"10.13039\/100005468","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022951","name":"Batten Disease Support and Research Association Australia","doi-asserted-by":"publisher","award":["Batten Disease Support and Research Association Australia"],"award-info":[{"award-number":["Batten Disease Support and Research Association Australia"]}],"id":[{"id":"10.13039\/501100022951","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CLN3 disease, or Juvenile Neuronal Ceroid Lipofuscinosis (JNCL), is a rare, genetic neurodegenerative condition, typically manifesting in the first decade of life and progressing in severity, with death typically occurring in early adulthood. Despite two decades of natural history research, a clear timeline of CLN3 disease symptom onset and progression remains poorly defined, limiting optimal patient management and therapeutic development. We conducted a literature review and analysed the natural history data to better understand the age of core symptom onset and chronological disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A literature review was undertaken using a pre-defined search strategy focused on CLN3 disease natural history studies, where age at onset for one or more core symptoms was reported in cohorts of \u2265\u200915 subjects. For each symptom, weighted mean age at onset and weighted standard deviation were calculated, with 95% confidence intervals derived from the weighted standard error. Symptom onset ages were compared using ANOVA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified nine natural history studies that met our pre-defined criteria. In total, 423 discrete patients aged between 4 and 39 years were reported. Thirteen core symptoms and a weighted average age at onset and weighted standard deviation were (in years): vision loss (6.1\u2009\u00b1\u20091.6,\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009254), behavioural changes (8.5\u2009\u00b1\u20093.9,\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009194), cognitive decline (9.3\u2009\u00b1\u20093.1,\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009219), seizures (10.2\u2009\u00b1\u20093.0,\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009243), sleep disturbance (11.0\u2009\u00b1\u20096.1,\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009111), motor decline (11.0\u2009\u00b1\u20093.8,\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009108), complete blindness (11.4\u2009\u00b1\u20093.6,\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009171), speech and language impairment (12.7\u2009\u00b1\u20094.8,\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009136), Parkinsonian gait (14.1\u2009\u00b1\u20092.5,\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009111), cardiac manifestations (17.8\u2009\u00b1\u20094.4,\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200945), loss of independent walking (19.5\u2009\u00b1\u20093.2,\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200970), feeding difficulties requiring enteral feeding tube (22.0\u2009\u00b1\u20091.6,\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200935), and death (22.4\u2009\u00b1\u20094.4,\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200995).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This comprehensive summary of available natural history data illustrates mean age at onset of 13 core symptoms of CLN3 disease, and characterises a chronological timeline of disease progression. These results provide much-needed practical, anticipatory guidance to those involved in caring for individuals with CLN3 disease, and serve to highlight the critical importance of collecting globally standardised, quantifiable, longitudinal data for optimising patient management and advancing therapeutic approaches for CLN3 disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04174-5","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T14:04:53Z","timestamp":1767794693000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A timeline of symptom onset and disease progression in CLN3 disease"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3302-7416","authenticated-orcid":false,"given":"Ineka T.","family":"Whiteman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony L.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika F.","family":"Augustine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan D.","family":"Bindoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather L.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Mink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Vermilion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Vierhile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather R.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"4174_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/dnnd.S111967","volume":"6","author":"JR Ostergaard","year":"2016","unstructured":"Ostergaard JR. Juvenile neuronal ceroid lipofuscinosis (Batten disease): current insights. Degener Neurol Neuromuscul Dis. 2016;6:73\u201383. https:\/\/doi.org\/10.2147\/dnnd.S111967. PMC6053093.","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"3","key":"4174_CR2","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10545-011-9421-6","volume":"35","author":"J Cialone","year":"2012","unstructured":"Cialone J, Adams H, Augustine EF, Marshall FJ, Kwon JM, Newhouse N, et al. Females experience a more severe disease course in Batten disease. J Inherit Metab Dis. 2012;35(3):549\u201355. https:\/\/doi.org\/10.1007\/s10545-011-9421-6.","journal-title":"J Inherit Metab Dis"},{"issue":"9","key":"4174_CR3","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1177\/0883073813494268","volume":"28","author":"JW Mink","year":"2013","unstructured":"Mink JW, Augustine EF, Adams HR, Marshall FJ, Kwon JM. Classification and natural history of the neuronal ceroid lipofuscinoses. J Child Neurol. 2013;28(9):1101\u20135. https:\/\/doi.org\/10.1177\/0883073813494268.","journal-title":"J Child Neurol"},{"key":"4174_CR4","doi-asserted-by":"crossref","unstructured":"Mole SE, Williams RE, Goebel HH, editors. The neuronal ceroid lipofuscinoses (Batten disease). Oxford: Oxford University Press; 2011.","DOI":"10.1093\/med\/9780199590018.001.0001"},{"issue":"2","key":"4174_CR5","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.ymgme.2008.11.093","volume":"96","author":"J Mink","year":"2009","unstructured":"Mink J. Longitudinal studies in Batten disease. Mol Genet Metab. 2009;96(2):S32. https:\/\/doi.org\/10.1016\/j.ymgme.2008.11.093.","journal-title":"Mol Genet Metab"},{"key":"4174_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2016.08.031","author":"DE Sleat","year":"2016","unstructured":"Sleat DE, Gedvilaite E, Zhang Y, Lobel P, Xing J. Analysis of large-scale whole exome sequencing data to determine the prevalence of genetically-distinct forms of neuronal ceroid lipofuscinosis. Gene. 2016;593(2):284\u201391. https:\/\/doi.org\/10.1016\/j.gene.2016.08.031."},{"issue":"2","key":"4174_CR7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1086\/514846","volume":"61","author":"PB Munroe","year":"1997","unstructured":"Munroe PB, Mitchison HM, O\u2019Rawe AM, Anderson JW, Boustany RM, Lerner TJ, et al. Spectrum of mutations in the Batten disease gene, CLN3. Am J Hum Genet. 1997;61(2):310\u20136. https:\/\/doi.org\/10.1086\/514846.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"4174_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2217\/clp.11.70","volume":"7","author":"SL Cotman","year":"2012","unstructured":"Cotman SL, Staropoli JF. The juvenile Batten disease protein, CLN3, and its role in regulating anterograde and retrograde post-Golgi trafficking. Clin Lipidol. 2012;7(1):79\u201391. https:\/\/doi.org\/10.2217\/clp.11.70.","journal-title":"Clin Lipidol"},{"key":"4174_CR9","doi-asserted-by":"publisher","first-page":"754045","DOI":"10.3389\/fneur.2021.754045","volume":"12","author":"E Gardner","year":"2021","unstructured":"Gardner E, Mole SE. The genetic basis of phenotypic heterogeneity in the neuronal ceroid lipofuscinoses. Front Neurol. 2021;12:754045. https:\/\/doi.org\/10.3389\/fneur.2021.754045.","journal-title":"Front Neurol"},{"key":"4174_CR10","doi-asserted-by":"publisher","unstructured":"Mole SE, Cotman SL. (2015) Genetics of the neuronal ceroid lipofuscinoses (Batten disease). Biochim biophys Acta. 1852(10 Pt B): 2237\u201341. https:\/\/doi.org\/10.1016\/j.bbadis.2015.05.011. PMC4567481.","DOI":"10.1016\/j.bbadis.2015.05.011"},{"key":"4174_CR11","unstructured":"Batten Disease Support and Research Australia. Family Register: BDSRA Australia. 2025. Available from: https:\/\/bdsraaustralia.org\/resources\/#bdsrasupport_register"},{"key":"4174_CR12","unstructured":"University College London (UCL). NCL disease: mutation and patient database. Available from https:\/\/www.ucl.ac.uk\/ncl-disease . Accessed June 20, 2024."},{"key":"4174_CR13","unstructured":"Batten Disease Support Research, and Advocacy Foundation. Family Register: BDSRA Foundation. 2024. Available from: https:\/\/bdsrafoundation.org\/family-register\/"},{"issue":"7","key":"4174_CR14","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/j.1469-8749.2010.03628.x","volume":"52","author":"HR Adams","year":"2010","unstructured":"Adams HR, Beck CA, Levy E, Jordan R, Kwon JM, Marshall FJ, et al. Genotype does not predict severity of behavioural phenotype in juvenile neuronal ceroid lipofuscinosis (Batten disease). Dev Med Child Neurol. 2010;52(7):637\u201343. https:\/\/doi.org\/10.1111\/j.1469-8749.2010.03628.x. PMC2895016.","journal-title":"Dev Med Child Neurol"},{"key":"4174_CR15","doi-asserted-by":"publisher","unstructured":"Honingh AK, Kruithof YL, Kuper WFE, van Hasselt PM, Sterkenburg PS. Towards understanding behaviour and emotions of children with CLN3 disease (Batten disease): patterns, problems and support for child and family. Int J Environ Res Public Health. 2022;19(10). https:\/\/doi.org\/10.3390\/ijerph19105895.","DOI":"10.3390\/ijerph19105895"},{"issue":"1","key":"4174_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13023-024-03119-8","volume":"19","author":"A Schulz","year":"2024","unstructured":"Schulz A, Patel N, Brudvig JJ, Stehr F, Weimer JM, Augustine EF. The parent and family impact of CLN3 disease: an observational survey-based study. Orphanet J Rare Dis. 2024;19(1):125. https:\/\/doi.org\/10.1186\/s13023-024-03119-8.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"4174_CR17","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/jimd.12366","volume":"44","author":"M Abdennadher","year":"2021","unstructured":"Abdennadher M, Inati S, Soldatos A, Norato G, Baker EH, Thurm A, et al. Seizure phenotype in CLN3 disease and its relation to other neurologic outcome measures. J Inherit Metab Dis. 2021;44(4):1013\u201320. https:\/\/doi.org\/10.1002\/jimd.12366.","journal-title":"J Inherit Metab Dis"},{"key":"4174_CR18","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1212\/WNL.0b013e31821435bd","volume":"76","author":"JR \u00d8stergaard","year":"2011","unstructured":"\u00d8stergaard JR, Rasmussen TB, M\u00f8lgaard H. Cardiac involvement in juvenile neuronal ceroid lipofuscinosis (Batten disease). Neurology. 2011;76:1245\u201351. . https:\/\/doi.org\/10.1212\/WNL.0b013e31821435bd","journal-title":"Neurology"},{"issue":"11\u201312","key":"4174_CR19","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.2119\/molmed.2010.00241","volume":"17","author":"AH Lebrun","year":"2011","unstructured":"Lebrun AH, Moll-Khosrawi P, Pohl S, Makrypidi G, Storch S, Kilian D, et al. Analysis of potential biomarkers and modifier genes affecting the clinical course of CLN3 disease. Mol Med. 2011;17(11\u201312):1253\u201361. https:\/\/doi.org\/10.2119\/molmed.2010.00241.","journal-title":"Mol Med"},{"key":"4174_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.yebeh.2019.02.020","volume":"94","author":"V Arntsen","year":"2019","unstructured":"Arntsen V, Strandheim J, Helland IB, Sand T, Brodtkorb E. Epileptological aspects of juvenile neuronal ceroid lipofuscinosis (CLN3 disease) through the lifespan. Epilepsy Behav. 2019;94:59\u201364. https:\/\/doi.org\/10.1016\/j.yebeh.2019.02.020.","journal-title":"Epilepsy Behav"},{"issue":"2","key":"4174_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10545-018-0143-x","volume":"41","author":"WFE Kuper","year":"2018","unstructured":"Kuper WFE, van Alfen C, Rigterink RH, Fuchs SA, van Genderen MM, van Hasselt PM. Timing of cognitive decline in CLN3 disease. J Inherit Metab Dis. 2018;41(2):257\u201361. https:\/\/doi.org\/10.1007\/s10545-018-0143-x.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"4174_CR22","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1212\/wnl.0000000000007773","volume":"93","author":"WFE Kuper","year":"2019","unstructured":"Kuper WFE, van Alfen C, van Eck L, Huijgen BCH, Nieuwenhuis EES, van Brussel M, et al. Motor function impairment is an early sign of CLN3 disease. Neurology. 2019;93(3):e293\u20137. https:\/\/doi.org\/10.1212\/wnl.0000000000007773.","journal-title":"Neurology"},{"issue":"9","key":"4174_CR23","doi-asserted-by":"publisher","first-page":"165480","DOI":"10.1016\/j.bbadis.2019.05.016","volume":"1866","author":"B Elmerskog","year":"2020","unstructured":"Elmerskog B, T\u00f8ssebro AG, Atkinson R, Rokne S, Cole B, Ockelford A, et al. Overview of advances in educational and social supports for young persons with NCL disorders. Biochim Biophys Acta Mol Basis Dis. 2020;1866(9):165480. https:\/\/doi.org\/10.1016\/j.bbadis.2019.05.016.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"6","key":"4174_CR24","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/j.1651-2227.1988.tb10770.x","volume":"77","author":"A Kohlsch\u00fctter","year":"1988","unstructured":"Kohlsch\u00fctter A, Laabs R, Albani M. Juvenile neuronal ceroid lipofuscinosis (JNCL): quantitative description of its clinical variability. Acta Paediatr Scand. 1988;77(6):867\u201372. https:\/\/doi.org\/10.1111\/j.1651-2227.1988.tb10770.x.","journal-title":"Acta Paediatr Scand"},{"issue":"1","key":"4174_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3109\/13816810.2014.977492","volume":"36","author":"AK Nielsen","year":"2015","unstructured":"Nielsen AK, Drack AV, Ostergaard JR. Cataract and glaucoma development in juvenile neuronal ceroid lipofuscinosis (batten disease). Ophthalmic Genet. 2015;36(1):39\u201342. https:\/\/doi.org\/10.3109\/13816810.2014.977492.","journal-title":"Ophthalmic Genet"},{"issue":"23","key":"4174_CR26","doi-asserted-by":"publisher","first-page":"e2436","DOI":"10.1212\/wnl.0000000000009454","volume":"94","author":"MC Masten","year":"2020","unstructured":"Masten MC, Williams JD, Vermilion J, Adams HR, Vierhile A, Collins A, et al. The CLN3 disease staging system: A new tool for clinical research in Batten disease. Neurology. 2020;94(23):e2436\u201340. https:\/\/doi.org\/10.1212\/wnl.0000000000009454.","journal-title":"Neurology"},{"issue":"4","key":"4174_CR27","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/dmcn.12634","volume":"57","author":"EF Augustine","year":"2015","unstructured":"Augustine EF, Adams HR, Beck CA, Vierhile A, Kwon J, Rothberg PG, et al. Standardized assessment of seizures in patients with juvenile neuronal ceroid lipofuscinosis. Dev Med Child Neurol. 2015;57(4):366\u201371. https:\/\/doi.org\/10.1111\/dmcn.12634.","journal-title":"Dev Med Child Neurol"},{"issue":"2","key":"4174_CR28","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.ymgme.2012.11.170","volume":"108","author":"J Mink","year":"2013","unstructured":"Mink J, Augustine EF, Marshall FJ, Adams HR, Kwon JM, Vierhile A, et al. The natural history of juvenile Batten disease (JNCL; CLN3 disease). Mol Genet Metab. 2013;108(2):S66. https:\/\/doi.org\/10.1016\/j.ymgme.2012.11.170.","journal-title":"Mol Genet Metab"},{"issue":"11","key":"4174_CR29","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/jnen\/nlab064","volume":"80","author":"LP Evans","year":"2021","unstructured":"Evans LP, Gibson-Corley KN, Mullins RF, Tucker BA, Trent A, Stone EM, et al. An unusual presentation of CLN3-Associated Batten disease with classic histopathologic and ultrastructural findings. J Neuropathol Exp Neurol. 2021;80(11):1081\u20134. https:\/\/doi.org\/10.1093\/jnen\/nlab064.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"4174_CR30","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/ana.410430118","volume":"43","author":"KE Wisniewski","year":"1998","unstructured":"Wisniewski KE, Zhong N, Kaczmarski W, Kaczmarski A, Kida E, Brown WT, et al. Compound heterozygous genotype is associated with protracted juvenile neuronal ceroid lipofuscinosis. Ann Neurol. 1998;43(1):106\u201310. https:\/\/doi.org\/10.1002\/ana.410430118.","journal-title":"Ann Neurol"},{"key":"4174_CR31","doi-asserted-by":"publisher","unstructured":"Smirnov VM, Nassisi M, Solis Hernandez C, M\u00e9j\u00e9case C, El Shamieh S, Condroyer C, et al. Retinal phenotype of patients with isolated retinal degeneration due to CLN3 pathogenic variants in a French retinitis pigmentosa cohort. JAMA Ophthalmol. 2021;139(3):278\u201391. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.6089. PMC7844693.","DOI":"10.1001\/jamaophthalmol.2020.6089"},{"key":"4174_CR32","doi-asserted-by":"publisher","first-page":"101759","DOI":"10.1016\/j.ajoc.2022.101759","volume":"29","author":"A Honasoge","year":"2023","unstructured":"Honasoge A, Smith B. Invited editorial in regards to phenotypic variant of CLN3 mutation. Am J Ophthalmol Case Rep. 2023;29:101759. https:\/\/doi.org\/10.1016\/j.ajoc.2022.101759.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"4174_CR33","doi-asserted-by":"publisher","unstructured":"Ku CA, Hull S, Arno G, Vincent A, Carss K, Kayton R, et al. Detailed clinical phenotype and molecular genetic findings in CLN3-associated isolated retinal degeneration. JAMA Ophthalmol. 2017;135:(7):749\u2009\u2013\u200960. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.1401. PMC5710208.","DOI":"10.1001\/jamaophthalmol.2017.1401"},{"issue":"2","key":"4174_CR34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103\u201315. https:\/\/doi.org\/10.1016\/j.nmd.2017.11.005.","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"4174_CR35","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.nmd.2017.05.011","volume":"27","author":"EF Tizzano","year":"2017","unstructured":"Tizzano EF, Finkel RS. Spinal muscular atrophy: A changing phenotype beyond the clinical trials. Neuromuscul Disord. 2017;27(10):883\u20139. https:\/\/doi.org\/10.1016\/j.nmd.2017.05.011.","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"4174_CR36","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/s1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and Gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251\u201367. https:\/\/doi.org\/10.1016\/s1474-4422(18)30024-3.","journal-title":"Lancet Neurol"},{"issue":"5","key":"4174_CR37","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/s1474-4422(18)30026-7","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Colvin MK, et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol. 2018;17(5):445\u201355. https:\/\/doi.org\/10.1016\/s1474-4422(18)30026-7.","journal-title":"Lancet Neurol"},{"issue":"3","key":"4174_CR38","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ejpn.2012.10.011","volume":"17","author":"AK Nielsen","year":"2013","unstructured":"Nielsen AK, \u00d8stergaard JR. Do females with juvenile ceroid lipofuscinosis (Batten disease) have a more severe disease course? The Danish experience. Eur J Paediatr Neurol. 2013;17(3):265\u20138. https:\/\/doi.org\/10.1016\/j.ejpn.2012.10.011.","journal-title":"Eur J Paediatr Neurol"},{"issue":"12","key":"4174_CR39","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1177\/09622802211047348","volume":"30","author":"S Cai","year":"2021","unstructured":"Cai S, Zhou J, Pan J. Estimating the sample mean and standard deviation from order statistics and sample size in meta-analysis. Stat Methods Med Res. 2021;30(12):2701\u201319. https:\/\/doi.org\/10.1177\/09622802211047348.","journal-title":"Stat Methods Med Res"},{"key":"4174_CR40","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ajo.2020.07.015","volume":"220","author":"S Dulz","year":"2020","unstructured":"Dulz S, Atiskova Y, Wibbeler E, Wildner J, Wagenfeld L, Schwering C, et al. An ophthalmic rating scale to assess ocular involvement in juvenile CLN3 disease. Am J Ophthalmol. 2020;220:64\u201371. https:\/\/doi.org\/10.1016\/j.ajo.2020.07.015.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"4174_CR41","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10633-023-09930-1","volume":"146","author":"DH Sakti","year":"2023","unstructured":"Sakti DH, Cornish EE, Fraser CL, Nash BM, Sandercoe TM, Jones MM, et al. Early recognition of CLN3 disease facilitated by visual electrophysiology and multimodal imaging. Doc Ophthalmol. 2023;146(3):241\u201356. https:\/\/doi.org\/10.1007\/s10633-023-09930-1.","journal-title":"Doc Ophthalmol"},{"issue":"4","key":"4174_CR42","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.oret.2019.11.005","volume":"4","author":"GA Wright","year":"2020","unstructured":"Wright GA, Georgiou M, Robson AG, Ali N, Kalhoro A, Holthaus SK, et al. Juvenile Batten disease (CLN3): detailed ocular Phenotype, novel Observations, delayed Diagnosis, Masquerades, and prospects for therapy. Ophthalmol Retina. 2020;4(4):433\u201345. https:\/\/doi.org\/10.1016\/j.oret.2019.11.005.","journal-title":"Ophthalmol Retina"},{"issue":"9","key":"4174_CR43","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1177\/0883073813494813","volume":"28","author":"HR Adams","year":"2013","unstructured":"Adams HR, Mink JW. Neurobehavioral features and natural history of juvenile neuronal ceroid lipofuscinosis (Batten disease). J Child Neurol. 2013;28(9):1128\u201336. https:\/\/doi.org\/10.1177\/0883073813494813.","journal-title":"J Child Neurol"},{"issue":"4","key":"4174_CR44","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1017\/s0012162206000570","volume":"48","author":"H Adams","year":"2006","unstructured":"Adams H, de Blieck EA, Mink JW, Marshall FJ, Kwon J, Dure L, et al. Standardized assessment of behavior and adaptive living skills in juvenile neuronal ceroid lipofuscinosis. Dev Med Child Neurol. 2006;48(4):259\u201364. https:\/\/doi.org\/10.1017\/s0012162206000570.","journal-title":"Dev Med Child Neurol"},{"issue":"Pt 1","key":"4174_CR45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1365-2788.2005.00659.x","volume":"49","author":"ML B\u00e4ckman","year":"2005","unstructured":"B\u00e4ckman ML, Santavuori PR, Aberg LE, Aronen ET. Psychiatric symptoms of children and adolescents with juvenile neuronal ceroid lipofuscinosis. J Intellect Disabil Res. 2005;49(Pt 1):25\u201332. https:\/\/doi.org\/10.1111\/j.1365-2788.2005.00659.x.","journal-title":"J Intellect Disabil Res"},{"key":"4174_CR46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.autneu.2018.07.003","volume":"214","author":"JR \u00d8stergaard","year":"2018","unstructured":"\u00d8stergaard JR. Paroxysmal sympathetic hyperactivity in juvenile neuronal ceroid lipofuscinosis (Batten disease). Auton Neurosci. 2018;214:15\u20138. . https:\/\/doi.org\/10.1016\/j.autneu.2018.07.003","journal-title":"Auton Neurosci"},{"key":"4174_CR47","doi-asserted-by":"publisher","first-page":"1059082","DOI":"10.3389\/fpsyt.2023.1059082","volume":"14","author":"JR \u00d8stergaard","year":"2023","unstructured":"\u00d8stergaard JR. Etiology of anxious and fearful behavior in juvenile neuronal ceroid lipofuscinosis (CLN3 disease). Front Psychiatry. 2023;14:1059082. . https:\/\/doi.org\/10.3389\/fpsyt.2023.1059082","journal-title":"Front Psychiatry"},{"issue":"5","key":"4174_CR48","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/0883073807302603","volume":"22","author":"HR Adams","year":"2007","unstructured":"Adams HR, Kwon J, Marshall FJ, de Blieck EA, Pearce DA, Mink JW. Neuropsychological symptoms of juvenile-onset Batten disease: experiences from 2 studies. J Child Neurol. 2007;22(5):621\u20137. https:\/\/doi.org\/10.1177\/0883073807302603.","journal-title":"J Child Neurol"},{"issue":"Pt 1","key":"4174_CR49","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1046\/j.1365-2788.2001.00288.x","volume":"45","author":"S Lamminranta","year":"2001","unstructured":"Lamminranta S, Aberg LE, Autti T, Moren R, Laine T, Kaukoranta J, et al. Neuropsychological test battery in the follow-up of patients with juvenile neuronal ceroid lipofuscinosis. J Intellect Disabil Res. 2001;45(Pt 1):8\u201317. https:\/\/doi.org\/10.1046\/j.1365-2788.2001.00288.x.","journal-title":"J Intellect Disabil Res"},{"issue":"1","key":"4174_CR50","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ymgme.2022.09.001","volume":"137","author":"JB Eisengart","year":"2022","unstructured":"Eisengart JB, Daniel MH, Adams HR, Williams P, Kuca B, Shapiro E. Increasing precision in the measurement of change in pediatric neurodegenerative disease. Mol Genet Metab. 2022;137(1):201\u20139. https:\/\/doi.org\/10.1016\/j.ymgme.2022.09.001.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"4174_CR51","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1352\/1944-7558-125.6.475","volume":"125","author":"CA Farmer","year":"2020","unstructured":"Farmer CA, Kaat AJ, Thurm A, Anselm I, Akshoomoff N, Bennett A, et al. Person ability scores as an alternative to Norm-Referenced scores as outcome measures in studies of neurodevelopmental disorders. Am J Intellect Dev Disabil. 2020;125(6):475\u201380. https:\/\/doi.org\/10.1352\/1944-7558-125.6.475. PMC11485197.","journal-title":"Am J Intellect Dev Disabil"},{"issue":"1","key":"4174_CR52","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ymgme.2021.03.002","volume":"133","author":"EG Shapiro","year":"2021","unstructured":"Shapiro EG, Eisengart JB. The natural history of neurocognition in MPS disorders: A review. Mol Genet Metab. 2021;133(1):8\u201334. https:\/\/doi.org\/10.1016\/j.ymgme.2021.03.002.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"4174_CR53","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/s0887-8994(00)00138-7","volume":"22","author":"E Kirveskari","year":"2000","unstructured":"Kirveskari E, Partinen M, Salmi T, Sainio K, Telakivi T, H\u00e4m\u00e4l\u00e4inen M, et al. Sleep alterations in juvenile neuronal ceroid-lipofuscinosis. Pediatr Neurol. 2000;22(5):347\u201354. https:\/\/doi.org\/10.1016\/s0887-8994(00)00138-7.","journal-title":"Pediatr Neurol"},{"key":"4174_CR54","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.pediatrneurol.2016.02.009","volume":"59","author":"LM Lehwald","year":"2016","unstructured":"Lehwald LM, Pappa R, Steward S, de Los Reyes E. Neuronal ceroid lipofuscinosis and associated sleep abnormalities. Pediatr Neurol. 2016;59:30\u20135. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2016.02.009.","journal-title":"Pediatr Neurol"},{"issue":"1","key":"4174_CR55","doi-asserted-by":"publisher","first-page":"e12838","DOI":"10.1002\/jimd.12838","volume":"48","author":"LD Morison","year":"2025","unstructured":"Morison LD, Whiteman IT, Vogel AP, Tilbrook L, Fahey MC, Braden R, et al. Speech, Language and Non-verbal communication in CLN2 and CLN3 Batten disease. J Inherit Metab Dis. 2025;48(1):e12838. https:\/\/doi.org\/10.1002\/jimd.12838.","journal-title":"J Inherit Metab Dis"},{"key":"4174_CR56","doi-asserted-by":"publisher","first-page":"846240","DOI":"10.3389\/fneur.2022.846240","volume":"13","author":"MM Handrup","year":"2022","unstructured":"Handrup MM, M\u00f8lgaard H, Andersen BN, Ostergaard JR. Pacemaker implantation in juvenile neuronal ceroid lipofuscinosis (CLN3)-A Long-Term Follow-Up study. Front Neurol. 2022;13:846240. https:\/\/doi.org\/10.3389\/fneur.2022.846240.","journal-title":"Front Neurol"},{"key":"4174_CR57","doi-asserted-by":"publisher","unstructured":"Zi\u00f3\u0142kowska EA, Williams LL, Jansen MJ, Wang SH, Eultgen EM, Sharma J, et al. Enteric nervous system degeneration in human and murine CLN3 disease, is ameliorated by gene therapy in mice. bioRxiv. 2025. https:\/\/doi.org\/10.1101\/2025.01.29.635518. PMC11838464.","DOI":"10.1101\/2025.01.29.635518"},{"key":"4174_CR58","doi-asserted-by":"crossref","unstructured":"Atee M, Whiteman I, Lloyd R, Morris T. Behaviours and psychological symptoms of childhood dementia: two cases of psychosocial interventions. Palliat Care Soc Pract. In press 2024.","DOI":"10.1177\/26323524241273492"},{"key":"4174_CR59","doi-asserted-by":"publisher","first-page":"785841","DOI":"10.3389\/fneur.2022.785841","volume":"13","author":"M Nickel","year":"2022","unstructured":"Nickel M, Schulz A. Natural history studies in NCL and their expanding role in drug development: experiences from CLN2 disease and relevance for clinical trials. Front Neurol. 2022;13:785841. https:\/\/doi.org\/10.3389\/fneur.2022.785841.","journal-title":"Front Neurol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04174-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04174-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04174-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:16:07Z","timestamp":1781626567000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-025-04174-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4174"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04174-5","relation":{"references":[{"id-type":"doi","id":"10.1016\/j.gene.2016.08.031","asserted-by":"subject"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Each author has completed the ICJME declaration forms, none of which indicated any competing interests that may have influenced the validity of this research. Copies of the completed ICJME forms are available upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}